Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 29Burkitt Lymphoma 23Multiple Myeloma 21Lymphoma, Large B-Cell, Diffuse 21Leukemia, Myeloid, Acute 18Lymphoma, Non-Hodgkin 16Myelodysplastic Syndromes 15Lymphoma, B-Cell 14Lymphoma 14Recurrence 11Ovarian Neoplasms 11Lymphoma, Follicular 11Hodgkin Disease 11Triple Negative Breast Neoplasms 10Neoplasms 9Lymphoma, Mantle-Cell 9Leukemia, Lymphocytic, Chronic, B-Cell 9Breast Neoplasms 9Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 8Pancreatic Neoplasms 8Leukemia, Myelogenous, Chronic, BCR-ABL Positive 8Leukemia 8Hematologic Neoplasms 7Sarcoma 6Osteosarcoma 6Leukemia, Myelomonocytic, Chronic 6Colorectal Neoplasms 6Lymphoma, B-Cell, Marginal Zone 5Leukemia, Biphenotypic, Acute 5Graft vs Host Disease 5

Interventions

prednylidene 1etoposide phosphate 1deltacortene 1Vincristine 1Vinblastine 1Specimen Handling 1Procarbazine 1Prednisone 1Prednisolone 1Nivolumab 1Methylprednisolone 1Magnetic Resonance Spectroscopy 1Fluorodeoxyglucose F18 1Etoposide 1Doxorubicin 1Dacarbazine 1Cyclophosphamide 1Brentuximab Vedotin 1Bleomycin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 × Cyclophosphamide × 30 days × Clear all
NCT05675410 2026-06-03

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

National Cancer Institute (NCI)

Phase 3 Recruiting
1,875 enrolled
Lymphoid

Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡